Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.

The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operational efficiencies. The lawsuit claims defendants knew of significant problems with Fabric's viability that would negatively impact the business. Investors with losses exceeding $100K are encouraged to join the class action before the August 3, 2026 lead plaintiff deadline.

Rosen Law Firm announces a securities class action lawsuit against GeneDx Holdings Corp (WGS) for alleged false statements regarding the Fabric acquisition. The firm claims GeneDx made misleading statements about cost reduction and operational synergies that never materialized, causing investor losses. The deadline to join the class action is August 3, 2026.

GeneDx Holdings Corp. (WGS) investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability of its Fabric Genomics acquisition. GeneDx's stock dropped over 49% on May 4, 2026 after revealing a significant drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss directly attributable to Fabric Genomics.

GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information between April 16, 2025 and May 4, 2026. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, lowered full-year guidance from $540-$550M to $475-$490M, and took a $31.2M impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on the announcement. Investors with losses exceeding $100,000 have until August 3, 2026 to file lead plaintiff applications.

Rosen Law Firm reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when defendants knew of significant viability problems that would negatively impact the business.

GeneDx Holdings Corp. faces a securities fraud class action lawsuit for failing to disclose material information about its Fabric Genomics acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and took a $31.2 million impairment loss, resulting in a 49.2% stock price decline. Investors who purchased shares between April 16, 2025 and May 4, 2026 can file lead plaintiff applications by August 3, 2026.

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false statements about Fabric Genomics and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx revealed a $57.5 million operational loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price fell approximately 50% from $67.93 to $34.51 per share. Investors have until August 3, 2026 to apply as lead plaintiff.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements regarding the Fabric acquisition's impact on the company's financials and operations. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 3, 2026.

A securities fraud class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company misled investors about the strategic and financial benefits of its Fabric Genomics acquisition. On May 4, 2026, GeneDx disclosed missed revenue estimates, slashed full-year guidance, and recorded a $31.2 million impairment charge on Fabric, causing the stock to plummet 49.2% in a single session. The lead plaintiff deadline is August 3, 2026.

A securities fraud class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company misled investors about the strategic and financial benefits of its Fabric Genomics acquisition. On May 4, 2026, GeneDx disclosed missed revenue estimates, slashed full-year guidance, and recorded a $31.2 million impairment charge on Fabric, causing the stock to plummet 49.2% in a single session. The lead plaintiff deadline is August 3, 2026.